Drug Trial Radar · NCT07945275
A Superiority Study of Model-Guided Optimized Dosing Versus Empirical Dosing of Piperacillin/Tazobactam in the Treatment of Community-Acquired Pneumonia in Elderly Patients
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
118
Planned (sponsor's estimate)
Start
Jul 17, 2026
Primary completion
May 31, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Shandong UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 65 years, up to 110 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study tests a new way to give an antibiotic to older adults with pneumonia. Pneumonia is a lung infection. Piperacillin-tazobactam is an antibiotic. Doctors often use it to treat pneumonia in older adults. Right now, doctors usually give this drug every 8 hours. They let it drip into the vein over 3 hours. But early research suggests a different schedule may work better. This study will test giving the drug every 6 hours. The drip will last 4 hours. Researchers think this may help the drug fight germs better. The study will compare the usual schedule with the new schedule. Participants will join one of two groups. One group will get the usual schedule. The other group will get the new schedule. Researchers will check how well the drug works. They will also watch for side effects. They want to find the safest and most helpful way to give this drug. Adults aged 65 and older with community-acquired pneumonia can join. Community-acquired pneumonia is a lung infection that starts outside of a hospital.
Conditions
- PD Target Attainment Rate
- Pneumonia
- Elderly (People Aged 65 or More)
Interventions
Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®)Drug
Control arm (guideline-based conventional dosing): Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) 4500 mg administered as a 3-hour intravenous infusion every 8 hours (q8h), for a total treatment course of 5-14 days.
Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®)Other
Intervention arm (model-guided optimized dosing): Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) 4500 mg administered as a 4-hour intravenous infusion every 6 hours (q6h), for a total treatment course of 5-14 days. This arm adopts increased dosing frequency and prolonged infusion duration compared with the control arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of patients achieving the predefined pharmacodynamic (PD) target.Time frame: up to 1 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shandong Provincial Public Health Clinical Center
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.